162270-28-2

Basic information

• Product Name: 2-Pyridineacetonitrile, a-[5-bromo-4-fluoro-2-(methoxymethoxy)phenyl]-3-(methoxymethoxy)-
• CAS NO: 162270-28-2
• Molecular Formula: C17H16BrFN2O4
• Molecular Weight: 411.227
• Mol File: 162270-28-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-Pyridineacetonitrile, a-[5-bromo-4-fluoro-2-(methoxymethoxy)phenyl]-3-(methoxymethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridineacetonitrile, a-[5-bromo-4-fluoro-2-(methoxymethoxy)phenyl]-3-(methoxymethoxy)-(162270-28-2)
• EPA Substance Registry System: 2-Pyridineacetonitrile, a-[5-bromo-4-fluoro-2-(methoxymethoxy)phenyl]-3-(methoxymethoxy)-(162270-28-2)

Safety Data

• Hazardous Substances Data: 162270-28-2(Hazardous Substances Data)

Upstream product

• 1026238-28-7 5-Bromo-4-fluoro-2-methoxymethoxy-benzoic acid methoxymethyl ester 
• 162269-98-9 5-bromo-4-fluoro-2-methoxymethoxybenzylalcohol 
• 1644-71-9 5-bromo-4-fluoro-2-hydroxy-benzoic acid 
• 162271-10-5 2-Bromo-3-(methoxymethoxy)pyridine 
• 162269-99-0 5-bromo-4-fluoro-2-methoxymethoxybenzylcyanide 

Downstream Products

• 162267-73-4 (5-Bromo-4-fluoro-2-hydroxy-phenyl)-(3-hydroxy-pyridin-2-yl)-methanone O-tert-butyl-oxime 
• 162271-20-7 2-(5-bromo-4-cyano-2-methoxymethoxybenzoyl)-3-MethoxYmethoxypyridine 
• 162268-33-9 2-Bromo-4-[[(Z)-tert-butoxyimino]-(3-hydroxy-pyridin-2-yl)-methyl]-5-hydroxy-benzonitrile 
• 162271-23-0 2-(5-bromo-4-cyano-2-hydroxybenzoyl)-3-hydroxypyridine 
• 162271-34-3 (5-Bromo-4-fluoro-2-hydroxy-phenyl)-(3-hydroxy-pyridin-2-yl)-methanone 
• 162271-19-4 2-(5-bromo-4-fluoro-2-methoxymethoxybenzoyl)-3-methoxymethoxy pyridine 

Relevant articles and documents

Synthesis and biological activity of novel 2-(α- alkoxyimino)benzylpyridine derivatives as K+ channel openers

The search for novel K+ channel openers with a non-benzopyran skeleton, unlike cromakalim, led to the discovery of a new series of (Z)-2-(α- alkoxyimino)benzylpyridine derivatives. Synthesis was achieved by using a (Z)-dominant condensation reaction of henzoylpyridines with O- alkylhydroxylamines, followed by m-chloroperhenzoic acid (m-CPBA) oxidation. The compounds were tested for their vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2- and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for their effects on the coronary blood flow (CBF) after intracoronary injection in anesthetized dogs. A large number of the 2-(α- alkoxyimino)benzylpyridines strongly inhibited TEA and BaCl2-induced contraction, had no effect on 80 mM KCl-induced contraction, and increased the CBF to more than 200% of the basal flow at 10-30μg/dog. In particular, (Z)-2-[5-bromo-α-(tert-butoxyimino)-4-fluoro-2-hydroxybenzyl]-3- hydroxypyridine 1-oxide (7d) showed highly potent vasorelaxant activity (EC50=0.28μM) comparable to that of levcromakalim (EC50=0.17 μM), and gave a significantly longer-lasting increase (T ( 1/4 ) = 30 min) in the CBF compared to levcromakalim, nicorandil, nitroglycerin, or diltiazem (T( 1/4 )=5.2, 0.9, 0.4, and 2.2 min, respectively). It also exhibited a stable and long-lasting hypotensive effect (over 7h) upon oral administration of 1 mg/kg in spontaneously hypertensive rats (SHRs).